160 related articles for article (PubMed ID: 8902056)
21. New opportunities for the development of cancer immunotherapies.
Rosenberg SA
Cancer J Sci Am; 1998 May; 4 Suppl 1():S1-4. PubMed ID: 9619263
[No Abstract] [Full Text] [Related]
22. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
Panelli MC; Bettinotti MP; Lally K; Ohnmacht GA; Li Y; Robbins P; Riker A; Rosenberg SA; Marincola FM
J Immunol; 2000 Apr; 164(8):4382-92. PubMed ID: 10754339
[TBL] [Abstract][Full Text] [Related]
23. Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches.
Henderson RA; Elliott M; Hopkins D; Fan L; Houghton R; Wang T
Immunol Invest; 2000 May; 29(2):87-91. PubMed ID: 10854172
[No Abstract] [Full Text] [Related]
24. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
[TBL] [Abstract][Full Text] [Related]
25. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
Wang RF; Parkhurst MR; Kawakami Y; Robbins PF; Rosenberg SA
J Exp Med; 1996 Mar; 183(3):1131-40. PubMed ID: 8642255
[TBL] [Abstract][Full Text] [Related]
26. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.
Trajanoski Z; Maccalli C; Mennonna D; Casorati G; Parmiani G; Dellabona P
Cancer Immunol Immunother; 2015 Jan; 64(1):99-104. PubMed ID: 25164877
[TBL] [Abstract][Full Text] [Related]
27. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
28. The development of new cancer therapies based on the molecular identification of cancer regression antigens.
Rosenberg SA
Cancer J Sci Am; 1995; 1(2):90-100. PubMed ID: 9166458
[TBL] [Abstract][Full Text] [Related]
29. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion.
Zorn E; Hercend T
Eur J Immunol; 1999 Feb; 29(2):602-7. PubMed ID: 10064076
[TBL] [Abstract][Full Text] [Related]
30. T cell-defined melanoma antigens: toward a tumour-specific immunotherapy of the disease.
Parmiani G
Melanoma Res; 1993 Dec; 3(6):391-3. PubMed ID: 7909243
[No Abstract] [Full Text] [Related]
31. [Cytotoxic T-cell immune response against melanoma antigens].
Ayyoub M
Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
[No Abstract] [Full Text] [Related]
32. The potential of melanoma antigen expression in cancer therapy.
Gillespie AM; Coleman RE
Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
[TBL] [Abstract][Full Text] [Related]
33. T cells take aim at cancer.
Pardoll D
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
[No Abstract] [Full Text] [Related]
34. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
35. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
36. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
Boël P; Wildmann C; Sensi ML; Brasseur R; Renauld JC; Coulie P; Boon T; van der Bruggen P
Immunity; 1995 Feb; 2(2):167-75. PubMed ID: 7895173
[TBL] [Abstract][Full Text] [Related]
37. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
[TBL] [Abstract][Full Text] [Related]
38. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
Ioannides CG; Whiteside TL
Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
[TBL] [Abstract][Full Text] [Related]
39. Adoptive T-Cell Therapy for Cancer.
Yang JC; Rosenberg SA
Adv Immunol; 2016; 130():279-94. PubMed ID: 26923004
[TBL] [Abstract][Full Text] [Related]
40. High-resolution genomic analysis: the tumor-immune interface comes into focus.
Havel JJ; Chan TA
Genome Biol; 2015 Mar; 16(1):65. PubMed ID: 25853850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
